Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 7420796, 7 pages
https://doi.org/10.1155/2017/7420796
Review Article

Antidiabetic Drugs in Alzheimer’s Disease: Mechanisms of Action and Future Perspectives

1Neurology Imaging Unit, Imperial College London, London, UK
2Division of Geriatrics, Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy
3Center for Translational Medicine and Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA
4Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
5Istituti Clinici Scientifici Maugeri SpA Società Benefit, Telese Terme Institute (BN), Italy

Correspondence should be addressed to Nicola Ferrara; ti.aninu@arrefcin

Received 10 March 2017; Accepted 7 May 2017; Published 1 June 2017

Academic Editor: Soledad Ballesteros

Copyright © 2017 Grazia Daniela Femminella et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Diabetes mellitus (DM) and Alzheimer’s disease (AD) are two highly prevalent conditions in the elderly population and major public health burden. In the past decades, a pathophysiological link between DM and AD has emerged and central nervous system insulin resistance might play a significant role as a common mechanism; however, other factors such as inflammation and oxidative stress seem to contribute to the shared pathophysiological link. Both preclinical and clinical studies have evaluated the possible neuroprotective mechanisms of different classes of antidiabetic medications in AD, with some promising results. Here, we review the evidence on the mechanisms of action of antidiabetic drugs and their potential use in AD.